Allergan CEO gambles a multibillion-dollar franchise — and his company rep — on a high-stakes bet at an Indian casino op
Bioregnum — The view from Endpoints News
Allergan CEO Brent Saunders scored some heavyweight kudos last fall with a social contract that condemned predatory drug pricing by the likes of Martin Shkreli and outlined the company’s commitment to R&D and access. But on Friday he squandered whatever moral clout he may have earned along the way with a legal gambit that looked too clever by half.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.